Distance Travelled in Medical Education: What MedComms Agencies Need to Know in 2025

Posted in Proof & MeasurementTagged Distance Travelled, Hcp Education, Medcomms Agencies

The pharma industry’s question has changed. It used to be: “Did HCPs attend our education programme?” Now it is: “Did the programme change how they practise?” The metric that answers that second question is distance travelled, and MedComms agencies that can measure it are winning pharma tender processes that agencies without this capability are losing.

This guide explains what distance travelled means in medical education, why pharma clients increasingly require it, and how MedComms agencies can build it into their delivery infrastructure today.

What Is Distance Travelled in Medical Education?

Distance travelled is the measurable gap between where a healthcare professional (HCP) started, their baseline knowledge, confidence, or clinical behaviour, and where they arrived after completing a medical education programme.

A distance travelled score of 42 percentage points means the programme demonstrably moved HCPs 42% closer to the target clinical behaviour. That number can be presented to pharma medical affairs teams as evidence of programme ROI, included in regulatory filings, and used to justify programme renewal.

The term comes from competency-based medical education research and has been operationalised in pharma through frameworks like Moore’s Continuum of Educational Outcomes (Moore, Green & Gallis, 2009), which defines seven levels of educational impact. Distance travelled sits at Moore’s Level 5, Performance, the gold standard.

Why MedComms Agencies Are Being Asked for This Now

Three trends have converged to make distance travelled a standard pharma requirement:

• Medical affairs accountability has tightened. Pharma medical affairs budgets are scrutinised more closely than ever. Directors are being asked to justify education spend with evidence that goes beyond slide decks and attendance registers. Distance travelled data provides that evidence.
• Regulatory expectations are evolving. Across Europe and the US, there is increasing regulatory interest in evidence that medical education programmes produce real-world behaviour change, not just knowledge transfer. Agencies that can generate this data are ahead of the regulatory curve.
• Completion rate fatigue. Pharma clients have been burned by programmes that showed 90%+ completion rates but produced no measurable change in clinical practice. The industry has collectively moved on. “They completed it” is no longer enough.

The Four Components of a Distance Travelled Score

To generate a credible distance travelled score, a medical education programme needs:

• Baseline assessment. Measuring the HCP’s starting position, their knowledge, confidence in diagnosis or prescribing, or self-reported clinical behaviour, before education begins. This is the departure point.
• Immediate post-programme measurement. The same or equivalent questions answered immediately after the programme. This captures knowledge transfer.
• Sustained follow-up measurement. The same questions answered at 4 to 8 weeks post-programme. This captures whether the change has been sustained in practice, the clinically meaningful signal.
• Cohort-level aggregation. Individual scores aggregated across the HCP cohort, enabling statistical analysis and a clear proof report for pharma medical affairs.

The gap between the baseline score and the sustained follow-up score, corrected for any ceiling effects, is the distance travelled.

What This Means for MedComms Agency Infrastructure

Most MedComms agencies were built to create and deliver medical education content. They were not built to capture distance travelled data. The infrastructure required is fundamentally different:

• A platform that captures individual HCP responses at each measurement point
• Data architecture that links baseline, immediate, and follow-up responses to the same HCP (with GDPR-compliant pseudonymisation)
• Automated follow-up delivery (typically email or in-app prompts at 4 and 8 weeks)
• A reporting layer that aggregates data into a proof report format pharma medical affairs teams can use directly

Building this infrastructure from scratch is a 12 to 18 month project. The alternative is partnering with an infrastructure provider that has already built it, Yoke Health’s behaviour change measurement platform is built specifically for MedComms agency deployment.

The Competitive Advantage MedComms Agencies Gain from Distance Travelled

Agencies that can offer distance travelled measurement to pharma clients gain a structural advantage in three areas:

Tender differentiation. When pharma companies put medical education programmes out to tender, agencies that include a distance travelled measurement component in their proposal are addressing a need that most competitors cannot. This shifts the conversation from price and creative quality to proven outcome delivery.

Programme renewal. Pharma programme renewals are increasingly conditional on demonstrated impact. Agencies that generated distance travelled data from year one are in a strong position to justify renewal. Agencies that cannot show impact data are not.

Medical affairs relationships. Distance travelled data elevates the MedComms agency relationship from content supplier to strategic partner. When an agency can walk into a medical affairs review meeting with a proof report showing that the programme moved HCPs 38 percentage points closer to the target behaviour, the conversation changes.

How Yoke Health Delivers Distance Travelled Measurement

Yoke Health’s platform was built with distance travelled measurement as its core function. The three products, iHive, iCases, and iLearning, each capture interaction data at every touchpoint, enabling automated Moore’s Level 5 follow-up at 6 weeks and a standardised distance travelled proof report.

For MedComms agencies, this means:

• White-label deployment under the agency’s brand, pharma clients see the agency’s identity
• Pre-programme baseline capture built into the onboarding flow
• Automated 6-week follow-up delivered via the platform (no agency project management overhead)
• Proof reports generated automatically, formatted for pharma medical affairs teams
• GDPR-compliant data handling throughout

The infrastructure already exists. MedComms agencies access it without the 12 to 18 month build cost.

What a Good Distance Travelled Score Looks Like

One of the most common questions from MedComms agencies building distance travelled measurement for the first time is: what does a strong result actually look like?

The honest answer is that benchmarks vary significantly by therapeutic area, HCP population, programme format, and starting baseline. An oncology specialist cohort beginning with high baseline knowledge will show a smaller absolute distance travelled score than a GP cohort with limited prior exposure to the therapy area, even if the programme quality is identical.

That said, as a working framework drawn from published HCP education research and platform data:

• Under 15 percentage points: Below threshold. Something went wrong, either the baseline was too high (ceiling effect), the content failed to land, or the follow-up measurement was too soon after delivery for behaviour change to consolidate.
• 15 to 30 percentage points: Functional. The programme produced measurable movement. Worth investigating which modules underperformed and why.
• 30 to 50 percentage points: Strong. This is where most well-designed programmes with good content alignment land. Suitable for a pharma medical affairs presentation.
• Over 50 percentage points: Exceptional, or potentially indicative of an unusually low baseline. Flag for review before presenting. If the starting cohort genuinely had that little knowledge, that context belongs in the proof report.

The more useful benchmark than the absolute score is the trend across programmes. Agencies that can show improving distance travelled scores across successive programme iterations, the same therapy area, different cohorts, are demonstrating genuine programme quality improvement, not just measurement capability.

Distance Travelled and Regulatory Compliance

The growing regulatory interest in CME and accredited medical education outcomes is relevant here. Across Europe and the US, there is increasing scrutiny of whether accredited education programmes deliver the educational outcomes they claim.

For UK programmes, the ABPI Code of Practice requires that medical education is genuinely educational and not promotional in design or effect. Evidence of knowledge and behaviour change, the kind a distance travelled proof report provides, supports a clear line between educational intent and educational outcome. It is the documentation that answers the question: “How do you know the programme was educational rather than promotional?”

For US programmes, CME accreditation bodies including the ACCME are progressively requiring outcome data rather than participation data as evidence of programme effectiveness. The Moore’s Level 5 framework, Performance and Competence, which underpins distance travelled measurement maps directly onto the ACCME’s evolving outcome expectations.

MedComms agencies that instrument their programmes for distance travelled measurement now are building a compliance asset as well as a commercial differentiator. The data they collect today is the evidence file they will need when regulatory scrutiny of programme outcomes becomes a standard requirement, not an exception.

Frequently Asked Questions

What is the difference between a knowledge assessment and a distance travelled score?

A knowledge assessment measures what an HCP knows at a single point in time. A distance travelled score measures how far their knowledge, confidence, or behaviour has moved between two or more points in time, and critically, whether that change is sustained in practice.

Can distance travelled be measured for all types of medical education programmes?

Yes, though the measurement approach varies by format. iCases (live and on-demand case-based learning) captures distance travelled through discussion confidence scores. iHive (perpetual micro-education) captures it through repeated exposure and response tracking. iLearning (eLearning/CME) uses the standard pre/post/follow-up assessment model.

How long does it take to set up distance travelled measurement for a new programme?

With Yoke Health’s white-label infrastructure, MedComms agencies can deploy a new programme with distance travelled measurement built in within 48 hours. The baseline assessment structure, follow-up automation, and proof report templates are pre-configured.

Is distance travelled data suitable for regulatory submissions?

Distance travelled data generated through a validated assessment methodology, with pre-programme baseline, immediate post-measurement, and sustained follow-up, is appropriate for inclusion in medical affairs internal reporting and regulatory submissions where evidence of educational impact is required. Specific regulatory guidance varies by market.

Yoke Health delivers white-label medical education platforms for MedComms agencies. To see a distance travelled proof report from a live programme, book a 30-minute demo.

What is a realistic baseline score for HCPs entering a new therapy area programme?

Baseline scores vary considerably. In specialist HCP populations with prior exposure to the therapy area, baseline scores of 60 to 70% on knowledge measures are common, leaving limited room for dramatic distance travelled. In broader HCP populations or at pre-approval launch, baseline scores of 30 to 40% are more typical, providing meaningful headroom. The key is calibrating your programme expectations to the cohort reality, not an abstract benchmark.

Who owns the distance travelled data generated through a Yoke-powered programme?

The MedComms agency owns the distance travelled data for programmes they commission. Yoke Health provides the measurement infrastructure; the data generated belongs to the agency and their pharma client, handled under a data processing agreement. GDPR-compliant pseudonymisation means individual HCP data is never transferred to pharma clients in identifiable form, only cohort-level aggregates.

Industry Context & Sources

The following sources support the evidence frameworks discussed in this article:

• Pharma AI Training Programs: Curriculum Design & ROI, IntuitionLabs (2025). Kirkpatrick’s four-level framework applied to HCP education: Level 3 (Behaviour) maps directly to distance travelled measurement, tracking whether HCPs apply learning in clinical practice weeks after a programme ends.
• Digital Preceptorships: Medical Affairs Takes Training Beyond the Hospital, M-Phar. Case-based performance assessments and sustained engagement tracking, the practical building blocks of distance travelled measurement in a digital programme context.
• Pharma & Medtech Solutions for Effective Programs, Meplis. Industry benchmarks for participation and outcome measurement across pharmaceutical education programmes.

Related Reading

• Proof Reports in MedComms: What Pharma Clients Are Now Demanding
• HCP Education in Biotech: Why Measuring Behaviour Change Is the Only Metric That Matters
• We didn’t deploy AI to do our jobs. We built it into how we work.